Genetic Technologies
Genetic Technologies Limited is a molecular diagnostics company based in Fitzroy, Australia, focused on women's health management through predictive testing and assessment tools. Its flagship product, BREVAGenplus, is a clinically validated risk assessment test designed to evaluate non-hereditary breast cancer risk. The company markets this test to healthcare professionals, including those in breast health and imaging centers, as well as obstetricians and breast cancer specialists. In addition to BREVAGenplus, Genetic Technologies is developing a range of cancer risk assessment tests branded as GeneType, which includes tests for colorectal and breast cancer. The company also provides various genetic testing services encompassing medical, forensic, animal, and plant testing. Established in 1989, Genetic Technologies holds numerous international patents and has formed research collaborations with prestigious institutions such as the University of Melbourne and Memorial Sloan Kettering Cancer Center, reflecting its commitment to advancing cancer management solutions.
Top Regions
Top Stages
1 past transactions
EasyDNA
Acquisition in 2021
EasyDNA USA is a prominent provider of DNA and genetic testing services, catering to clients across the United States, Europe, and Asia. The company offers a comprehensive range of testing solutions, including paternity, relationship, prenatal, animal, clinical, health, and drug tests. These services aim to address various needs, such as resolving family issues, legal matters, and enhancing personal peace of mind. Over the years, EasyDNA has established partnerships with medical clinics and private practitioners, further extending its reach and impact in the genetic testing market.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.